Reproxalap ‐ A Novel Treatment Option for Allergic Conjunctivitis – A Comprehensive Narrative Review
Open Access
- 31 May 2026
- journal article
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72492
Abstract
Background and Aims: Allergic conjunctivitis is a prevalent, immune‐mediated hypersensitivity disorder of the ocular surface affecting 10%–20% of the global population. Current therapeutic options, while effective to some extent, are often limited by side effects and inconsistent efficacy. Despite its widespread impact, allergic conjunctivitis receives comparatively less clinical attention than other chronic allergic conditions. This review aims to assess the therapeutic potential and clinical efficacy of Reproxalap, a novel ophthalmic solution targeting reactive aldehyde species (RASP), for the treatment of allergic conjunctivitis. Methods: A narrative review was conducted analyzing the pharmacological profile of Reproxalap and its clinical performance in phase 2 and phase 3 clinical trials. These trials evaluated the drug's safety, tolerability, and efficacy based on symptom relief, particularly ocular itching and inflammation. Results: Reproxalap demonstrated early‐onset and broad‐spectrum anti‐inflammatory activity through RASP inhibition. By trapping free aldehydes and modulating inflammatory mediators like cytokines and chemokines, it significantly reduced ocular inflammation. Clinical trial data indicated statistically significant improvement in itching scores and sustained symptom relief in patients with allergic conjunctivitis. The drug also showed a favorable safety profile, with minimal adverse events reported. Conclusion: Reproxalap represents a first‐in‐class RASP inhibitor with promising efficacy and safety for the treatment of allergic conjunctivitis. Its unique mechanism of action and encouraging clinical trial outcomes support its potential as a valuable therapeutic alternative that may improve patient outcomes and could also be applicable in other inflammatory ocular conditions.Keywords
This publication has 43 references indexed in Scilit:
- Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field TrialOphthalmology and Therapy, 2022
- Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE TrialAmerican Journal of Ophthalmology, 2021
- Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye DiseaseAmerican Journal of Ophthalmology, 2021
- ICONAnnals of Allergy, Asthma & Immunology, 2020
- Emerging Therapeutics for Ocular Surface DiseaseCurrent Allergy and Asthma Reports, 2019
- Inflammation - From Molecular and Cellular Mechanisms to the Clinic2017
- Omalizumab Treatment of Vernal KeratoconjunctivitisJAMA Ophthalmology, 2016
- Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cellsExperimental Eye Research, 2008
- Lipid peroxidation: Mechanisms, inhibition, and biological effectsBiochemical and Biophysical Research Communications, 2005
- The central role of conjunctival mast cells in the pathogenesis of ocular allergyCurrent Allergy and Asthma Reports, 2002